Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations

Table 1 Noncytotoxic concentrations of chemotherapeutic agents (MTT assay)

Chemotherapeutic agents	EC* LNCaP	EC PCI-4B	EC HCT-116	EC HT-29
*Antimicrotubule agents*
Vinblastine (Velban)	100 nM	10 nM	ND	ND
Vincristine (Oncovin)	100 nM	0.1 nM	ND	ND
Paclitaxel (Taxol)	10 nM	0.1 nM	0.5 nM	5 nM
*Antimetabolites*
5-azacytidine (Vidaza)	100 nM	50 nM	ND	ND
Methotrexate (Rheumatrex, Trexall)	5 nM	5 nM	0.5 nM	ND
*Alkylating agents*
Cyclophosphamide (Cytoxan)	Resistant**	50 nM	50 nM	ND
Mitomycin C (Mutamycin)	500 nM	50 nM	ND	ND
*Topoisomerase inhibitors*
Doxorubicin (Adriamycin)	100 nM	50 nM	5 nM	5 nM
*Platinum agents*
Cisplatin (Platinol)	Resistant	Resistant	ND	ND
Carboplatin (Paraplatin)	Resistant	Resistant	ND	ND
*Hormonal agents*
Flutamide (Drogenil, Eulexin)	Resistant	Resistant	ND	ND
Tamoxifen (Nolvadex)	1000 nM	Resistant	ND	ND
*Others*
Bleomycin (Blenoxane)	100 nM	100 nM	ND	ND

*, EC, Effective concentration – the maximal concentration of a chemotherapeutic agent that caused no inhibition of tumor cell activity in the MTT assay.
**, Cells were considered resistant to the treatment when the EC value was greater than 1,000 nM.
LNCaP, human prostate cancer cell line; PCI-4B, human head and neck squamous cell carcinoma cell line; HCT-116 and HT-29, human colon cancer cell lines; MTT, (3-(4,5-Dimmethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) reduction assay; ND, not determined.

ISSN: 1479-5876